Vanda Pharmaceuticals Inc (VNDA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $5.13 (+0.39%), Market cap $0.38B, 52-week low–high $3.92 ~ $9.56.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for
Financial statements, price targets, institutional (13F) holdings and related news for Vanda Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Vanda Pharmaceuticals Inc trades at $5.13 (+0.39%). Real-time quotes and charts are available on BlackAll Trade.
Vanda Pharmaceuticals Inc has a market cap of about $0.38B.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio